trihexyphenidyl 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vasodilators 2745 144-11-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trihexyphenidyl
  • trihexyphenidyl hydrochloride
  • benzhexol
  • benzhexol hydrochloride
  • trihexyphenidyl HCl
  • benzhexol HCl
One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
  • Molecular weight: 301.47
  • Formula: C20H31NO
  • CLOGP: 5.15
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 23.47
  • ALOGS: -4.98
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.63 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.601 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.057 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 26.669 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 12.274 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 11.740 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 27 % High 1
herg hERG pIC50 5.341 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 4.276 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 15.276 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 15.430 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,SIK3,TEK,TGFBR1 36
kinase-selectivity-class AXL,GRK2,PDK4 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.527 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.303 High 1
mh-clint Mouse hepatocyte intrinsic clearance 78.343 High 1
mppb Mouse plasma protein binding (% unbound) 14.550 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.099 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 25.830 % High 1
rat-kpuu-brain Rat brain Kpuu 0.478 % High 1
rh-clint Rat hepatocyte intrinsic clearance 195.434 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 35.040 % High 1
rppb Rat plasma protein binding (% unbound) 17.750 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 628.058 uM High 1

Approvals:

DateAgencyCompanyOrphan
May 13, 1949 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 141.30 26.05 47 4671 16772 90606957
Drug interaction 131.15 26.05 111 4607 276342 90347387
Dyskinesia 105.86 26.05 47 4671 36487 90587242
Coma 104.46 26.05 58 4660 72574 90551155
Tardive dyskinesia 97.62 26.05 32 4686 10898 90612831
Extrapyramidal disorder 77.90 26.05 30 4688 16273 90607456
Neuroleptic malignant syndrome 76.51 26.05 29 4689 15067 90608662
Hallucinations, mixed 72.37 26.05 22 4696 5867 90617862
Parkinsonism 71.21 26.05 27 4691 14038 90609691
Suicide attempt 64.02 26.05 43 4675 75356 90548373
Urinary retention 62.16 26.05 33 4685 37711 90586018
Toxicity to various agents 61.15 26.05 75 4643 287771 90335958
Muscle rigidity 60.14 26.05 24 4694 14285 90609444
Intentional overdose 57.76 26.05 44 4674 93790 90529939
Sinus tachycardia 55.80 26.05 28 4690 28485 90595244
Cognitive disorder 55.15 26.05 38 4680 69369 90554360
Tremor 53.68 26.05 52 4666 153121 90470608
Somnolence 51.85 26.05 59 4659 209025 90414704
Myoclonus 50.22 26.05 23 4695 19145 90604584
Pneumonia aspiration 48.92 26.05 29 4689 40911 90582818
Disorientation 46.91 26.05 29 4689 44085 90579644
Hallucination 45.20 26.05 33 4685 65926 90557803
Hyperchloraemia 43.82 26.05 10 4708 878 90622851
Apraxia 43.62 26.05 12 4706 2250 90621479
Mydriasis 42.45 26.05 19 4699 14993 90608736
Perseveration 42.34 26.05 8 4710 277 90623452
Intentional product misuse 42.34 26.05 36 4682 89568 90534161
Hyperreflexia 41.89 26.05 15 4703 6642 90617087
Speech disorder 41.09 26.05 27 4691 45558 90578171
Hypernatraemia 40.33 26.05 16 4702 9371 90614358
Transient aphasia 39.89 26.05 6 4712 49 90623680
Schizophrenia 39.39 26.05 18 4700 14896 90608833
Drug abuse 38.73 26.05 33 4685 82314 90541415
Oculogyric crisis 38.04 26.05 11 4707 2468 90621261
Salivary hypersecretion 37.34 26.05 15 4703 9077 90614652
Hallucination, auditory 35.16 26.05 17 4701 15958 90607771
Abulia 35.07 26.05 8 4710 701 90623028
Overdose 33.26 26.05 41 4677 157668 90466061
Drug screen false positive 32.80 26.05 8 4710 935 90622794
Macroprolactinaemia 31.41 26.05 4 4714 7 90623722
Delusion 31.28 26.05 15 4703 13825 90609904
Ataxia 30.33 26.05 16 4702 18026 90605703
Onychophagia 30.10 26.05 5 4713 81 90623648
Off label use 29.41 26.05 124 4594 1102128 89521601
Inappropriate antidiuretic hormone secretion 29.16 26.05 16 4702 19489 90604240
Pain 29.12 26.05 8 4710 996333 89627396
Cytopenia 27.99 26.05 15 4703 17434 90606295
Depressed level of consciousness 27.92 26.05 26 4692 72758 90550971
Drug ineffective for unapproved indication 27.89 26.05 25 4693 66619 90557110
Rhabdomyolysis 27.12 26.05 22 4696 51234 90572495
Persecutory delusion 27.06 26.05 9 4709 3199 90620530
Locked-in syndrome 26.77 26.05 6 4712 486 90623243
Electrocardiogram QT prolonged 26.10 26.05 25 4693 72431 90551298

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 160.78 25.44 103 6830 53451 42560951
Extrapyramidal disorder 142.27 25.44 64 6869 16348 42598054
Brain scan abnormal 140.64 25.44 34 6899 1205 42613197
Cerebral artery thrombosis 140.37 25.44 34 6899 1215 42613187
Neuroleptic malignant syndrome 128.81 25.44 65 6868 21407 42592995
Wrong patient received product 125.62 25.44 39 6894 3544 42610858
Areflexia 107.50 25.44 35 6898 3708 42610694
Dystonia 101.75 25.44 47 6886 12743 42601659
Hallucination 92.89 25.44 76 6857 57431 42556971
Respiratory distress 86.50 25.44 64 6869 41756 42572646
Somnolence 81.18 25.44 107 6826 140998 42473404
Failure to suspend medication 77.62 25.44 17 6916 385 42614017
Hemiplegia 72.31 25.44 32 6901 7847 42606555
Tardive dyskinesia 63.15 25.44 28 6905 6896 42607506
Facial paralysis 58.14 25.44 32 6901 12531 42601871
Drug abuse 56.43 25.44 77 6856 104694 42509708
Parkinsonism 54.57 25.44 29 6904 10594 42603808
Ischaemic stroke 52.74 25.44 37 6896 22196 42592206
Toxicity to various agents 50.02 25.44 113 6820 229023 42385379
Disease recurrence 47.39 25.44 39 6894 29639 42584763
Antipsychotic drug level increased 46.22 25.44 20 6913 4646 42609756
Dyskinesia 46.15 25.44 36 6897 25354 42589048
Accidental death 43.42 25.44 17 6916 3066 42611336
Delusion 43.27 25.44 28 6905 14706 42599696
Pneumonia aspiration 40.16 25.44 45 6888 50033 42564369
Drug interaction 37.87 25.44 112 6821 266887 42347515
Catatonia 37.70 25.44 19 6914 6220 42608182
Salivary hypersecretion 37.67 25.44 23 6910 10920 42603482
Faecaloma 37.61 25.44 19 6914 6251 42608151
Tremor 37.45 25.44 61 6872 96868 42517534
Rhabdomyolysis 37.01 25.44 54 6879 77965 42536437
Parkinsonism hyperpyrexia syndrome 36.40 25.44 9 6924 350 42614052
Schizophrenia 33.34 25.44 21 6912 10529 42603873
Cerebral amyloid angiopathy 33.23 25.44 8 6925 278 42614124
Muscle rigidity 33.17 25.44 22 6911 12037 42602365
Oculogyric crisis 33.09 25.44 12 6921 1753 42612649
Parkinsonian rest tremor 32.07 25.44 8 6925 323 42614079
Delirium 30.37 25.44 40 6893 52479 42561923
Diarrhoea 30.11 25.44 19 6914 460830 42153572
Prothrombin level decreased 29.68 25.44 10 6923 1176 42613226
Dysarthria 28.92 25.44 34 6899 39773 42574629
Miosis 28.71 25.44 21 6912 13425 42600977
White blood cell count increased 28.67 25.44 36 6897 45051 42569351
Akathisia 28.58 25.44 19 6914 10432 42603970
Salivary gland cancer stage IV 28.36 25.44 5 6928 34 42614368
Respiratory failure 27.66 25.44 63 6870 128069 42486333
Poisoning 27.05 25.44 21 6912 14678 42599724
Colitis ischaemic 26.97 25.44 16 6917 7210 42607192
Hallucination, auditory 26.84 25.44 21 6912 14843 42599559
Spleen congestion 26.61 25.44 7 6926 350 42614052
Hepatitis acute 26.21 25.44 17 6916 8958 42605444
Fatigue 25.75 25.44 20 6913 435621 42178781

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 262.18 23.02 157 10908 117712 110460522
Dystonia 232.54 23.02 90 10975 25715 110552519
Extrapyramidal disorder 229.67 23.02 92 10973 28775 110549459
Neuroleptic malignant syndrome 205.11 23.02 89 10976 33970 110544264
Tardive dyskinesia 153.75 23.02 56 11009 13523 110564711
Drug interaction 151.17 23.02 216 10849 499967 110078267
Brain scan abnormal 143.65 23.02 33 11032 1538 110576696
Dyskinesia 139.41 23.02 78 10987 51368 110526866
Cerebral artery thrombosis 136.41 23.02 32 11033 1636 110576598
Parkinsonism 127.11 23.02 56 11009 22131 110556103
Somnolence 124.67 23.02 151 10914 297298 110280936
Hallucination 123.48 23.02 93 10972 101339 110476895
Wrong patient received product 104.29 23.02 35 11030 6639 110571595
Drug abuse 103.33 23.02 107 10958 177304 110400930
Toxicity to various agents 101.20 23.02 176 10889 480379 110097855
Areflexia 99.87 23.02 34 11031 6735 110571499
Muscle rigidity 86.39 23.02 44 11021 23987 110554247
Respiratory distress 85.67 23.02 64 11001 68810 110509424
Pneumonia aspiration 84.74 23.02 68 10997 81165 110497069
Tremor 81.91 23.02 101 10964 202131 110376103
Salivary hypersecretion 80.92 23.02 38 11027 17383 110560851
Failure to suspend medication 76.80 23.02 16 11049 470 110577764
Oculogyric crisis 75.69 23.02 24 11041 3808 110574426
Rhabdomyolysis 74.38 23.02 75 10990 120326 110457908
Suicide attempt 64.94 23.02 65 11000 103329 110474905
Catatonia 63.03 23.02 28 11037 11272 110566962
Antipsychotic drug level increased 61.50 23.02 24 11041 6991 110571243
Ischaemic stroke 59.62 23.02 42 11023 41221 110537013
Urinary retention 59.55 23.02 52 11013 69631 110508603
Delusion 58.88 23.02 34 11031 23721 110554513
Disorientation 56.93 23.02 51 11014 70620 110507614
Hallucinations, mixed 56.52 23.02 24 11041 8669 110569565
Hallucination, auditory 55.56 23.02 34 11031 26363 110551871
Schizophrenia 53.46 23.02 31 11034 21795 110556439
Facial paralysis 53.05 23.02 32 11033 24182 110554052
Hemiplegia 52.23 23.02 31 11034 22751 110555483
Diarrhoea 51.44 23.02 25 11040 1139480 109438754
Drug screen false positive 50.92 23.02 14 11051 1355 110576879
Pain 49.48 23.02 17 11048 954938 109623296
Cognitive disorder 49.48 23.02 52 11013 87459 110490775
Akathisia 49.21 23.02 27 11038 17086 110561148
Hypernatraemia 48.17 23.02 27 11038 17806 110560428
Sinus tachycardia 47.99 23.02 38 11027 44455 110533779
Faecaloma 46.99 23.02 25 11040 14883 110563351
Agitation 44.98 23.02 56 11009 112995 110465239
Behaviour disorder 44.66 23.02 21 11044 9626 110568608
Drug ineffective for unapproved indication 44.25 23.02 53 11012 102785 110475449
Intentional overdose 43.94 23.02 60 11005 132441 110445793
Psychotic disorder 43.49 23.02 38 11027 50899 110527335
Delirium 43.06 23.02 60 11005 134965 110443269
Overdose 41.91 23.02 80 10985 233714 110344520
Arthralgia 41.90 23.02 13 11052 779619 109798615
Disease recurrence 41.48 23.02 40 11025 60744 110517490
Respiratory depression 40.36 23.02 30 11035 31971 110546263
Accidental death 39.93 23.02 16 11049 4993 110573241
Confusional state 39.89 23.02 120 10945 468560 110109674
Speech disorder 39.18 23.02 39 11026 61530 110516704
Poisoning 38.31 23.02 28 11037 29077 110549157
Fatigue 37.47 23.02 40 11025 1215918 109362316
Intentional product misuse 36.46 23.02 55 11010 132849 110445385
Poisoning deliberate 36.18 23.02 26 11039 26305 110551929
Parkinsonism hyperpyrexia syndrome 35.89 23.02 9 11056 609 110577625
Altered state of consciousness 35.74 23.02 36 11029 57590 110520644
Dysarthria 35.60 23.02 43 11022 84078 110494156
Mydriasis 35.41 23.02 24 11041 22133 110556101
White blood cell count increased 35.40 23.02 46 11019 96796 110481438
On and off phenomenon 34.81 23.02 14 11051 4410 110573824
Hallucination, visual 34.72 23.02 30 11035 39575 110538659
Parkinsonian rest tremor 34.43 23.02 8 11057 392 110577842
Perseveration 33.91 23.02 8 11057 419 110577815
Hyperchloraemia 33.51 23.02 10 11055 1296 110576938
Psychiatric symptom 33.48 23.02 17 11048 9196 110569038
Miosis 33.21 23.02 23 11042 21960 110556274
Abnormal behaviour 33.07 23.02 29 11036 39010 110539224
Hyperammonaemia 32.30 23.02 19 11046 13713 110564521
Wrong patient 32.15 23.02 10 11055 1489 110576745
Neutrophil count increased 31.91 23.02 27 11038 34625 110543609
Dysphagia 31.85 23.02 56 11009 153544 110424690
Cerebral amyloid angiopathy 31.82 23.02 8 11057 547 110577687
Torticollis 31.74 23.02 12 11053 3209 110575025
Aggression 31.37 23.02 34 11031 59176 110519058
Myoclonus 30.98 23.02 26 11039 32972 110545262
Apraxia 30.63 23.02 12 11053 3528 110574706
Prothrombin level decreased 30.30 23.02 10 11055 1800 110576434
Hyperreflexia 30.16 23.02 16 11049 9469 110568765
Persecutory delusion 30.07 23.02 14 11051 6277 110571957
Macroprolactinaemia 28.80 23.02 4 11061 7 110578227
Abdominal discomfort 28.74 23.02 3 11062 393855 110184379
Psychomotor skills impaired 28.53 23.02 14 11051 7044 110571190
Inappropriate antidiuretic hormone secretion 28.38 23.02 25 11040 33826 110544408
Off label use 28.10 23.02 250 10815 1499935 109078299
Salivary gland cancer stage IV 27.72 23.02 5 11060 67 110578167
Spleen congestion 27.65 23.02 7 11058 492 110577742
Hypersensitivity 27.23 23.02 4 11061 403994 110174240
Electrocardiogram QT prolonged 26.96 23.02 43 11022 108917 110469317
Cardiac death 26.91 23.02 9 11056 1687 110576547
Ataxia 26.78 23.02 23 11042 30085 110548149
Withdrawal syndrome 25.96 23.02 23 11042 31357 110546877
Treatment noncompliance 25.63 23.02 34 11031 72956 110505278
Sexually inappropriate behaviour 25.60 23.02 7 11058 664 110577570
Respiratory failure 25.15 23.02 62 11003 215270 110362964
Onychophagia 25.01 23.02 5 11060 119 110578115
Abulia 25.01 23.02 8 11057 1305 110576929
Sudden death 24.52 23.02 20 11045 24375 110553859
Intestinal obstruction 23.82 23.02 28 11037 53199 110525035
Logorrhoea 23.59 23.02 11 11054 4946 110573288
Disturbance in attention 23.51 23.02 30 11035 61965 110516269
Hypothermia 23.21 23.02 20 11045 26282 110551952
Rash 23.08 23.02 29 11036 820935 109757299

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04AA01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
ANTICHOLINERGIC AGENTS
Tertiary amines
MeSH PA D000978 Antiparkinson Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D018727 Muscarinic Antagonists
CHEBI has role CHEBI:48407 antiparkinson drug

Related Drugs by ATC class:

N04AA Tertiary amines 9 drugs
biperidenbornaprinedexetimidemazaticolmetixenephenglutarimideprocyclidineprofenaminetropatepine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinsonism indication 32798002
Parkinson's disease indication 49049000 DOID:14330
Extrapyramidal disease indication 76349003
Arteriosclerotic Parkinsonism indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Shigellosis contraindication 36188001
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Dysuria contraindication 49650001
Paralytic ileus contraindication 55525008 DOID:8442
Ulcerative colitis contraindication 64766004 DOID:8577
Hiatal hernia contraindication 84089009 DOID:12642
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Thyrotoxicosis contraindication 90739004 DOID:7997
Myasthenia gravis contraindication 91637004 DOID:437
Tardive dyskinesia contraindication 102449007
Dysentery contraindication 111939009
Gastrointestinal obstruction contraindication 126765001
Bleeding contraindication 131148009
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Fever contraindication 386661006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Pseudomembranous enterocolitis contraindication 397683000
Gastric ulcer contraindication 397825006 DOID:10808
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.23 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST IC50 8.89 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M2 GPCR IC50 7.73 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.35 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR IC50 8.17 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR IC50 7.99 CHEMBL
Cytochrome P450 2D6 Enzyme IC50 5.61 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR IC50 7.58 CHEMBL

External reference:

IDSource
4019959 VUID
N0000148044 NUI
D00787 KEGG_DRUG
52-49-3 SECONDARY_CAS_RN
4017900 VANDF
4019959 VANDF
C0041009 UMLSCUI
CHEBI:9720 CHEBI
CHEMBL1490 ChEMBL_ID
DB00376 DRUGBANK_ID
CHEMBL1092 ChEMBL_ID
D014282 MESH_DESCRIPTOR_UI
5572 PUBCHEM_CID
7315 IUPHAR_LIGAND_ID
1318 INN_ID
6RC5V8B7PO UNII
10811 RXNORM
2986 MMSL
5628 MMSL
d00970 MMSL
001641 NDDF
004664 NDDF
2190009 SNOMEDCT_US
387120000 SNOMEDCT_US
387336005 SNOMEDCT_US
6RC5V8B7PO INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0658 SOLUTION 2 mg ORAL ANDA 22 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5335 TABLET 2 mg ORAL ANDA 9 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5337 TABLET 5 mg ORAL ANDA 9 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2994 TABLET 2 mg ORAL ANDA 9 sections
TRIHEXYPHENIDYL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51407-265 TABLET 2 mg ORAL ANDA 10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51407-266 TABLET 5 mg ORAL ANDA 10 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0633 TABLET 2 mg ORAL ANDA 10 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0634 TABLET 5 mg ORAL ANDA 10 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53808-0696 TABLET 5 mg ORAL ANDA 9 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54738-554 TABLET 2 mg ORAL ANDA 10 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54738-555 TABLET 5 mg ORAL ANDA 10 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 61748-054 SYRUP 2 mg ORAL ANDA 21 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62135-065 SOLUTION 2 mg ORAL ANDA 13 sections
Trihexyphenidyl Hydrochloride Human Prescription Drug Label 1 63850-0021 TABLET 2 mg ORAL ANDA 19 sections
Trihexyphenidyl Hydrochloride Human Prescription Drug Label 1 63850-0022 TABLET 5 mg ORAL ANDA 19 sections
Trihexyphenidyl Hydrochloride Human Prescription Drug Label 1 64725-0161 TABLET 5 mg ORAL ANDA 20 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68151-2782 TABLET 2 mg ORAL ANDA 9 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 69452-241 TABLET 2 mg ORAL ANDA 20 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 69452-242 TABLET 5 mg ORAL ANDA 20 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-1140 TABLET 5 mg ORAL ANDA 9 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-1612 TABLET 2 mg ORAL ANDA 9 sections
Trihexyphenidyl Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-1657 TABLET 5 mg ORAL ANDA 9 sections
TRIHEXYPHENIDYL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 70518-2409 TABLET 5 mg ORAL ANDA 10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 70518-2410 TABLET 2 mg ORAL ANDA 10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE Human Prescription Drug Label 1 70954-211 TABLET 5 mg ORAL ANDA 10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE Human Prescription Drug Label 1 70954-212 TABLET 2 mg ORAL ANDA 10 sections